Lista de obras -

4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors

artículo científico publicado en 2016

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

artículo científico publicado en 2017

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss

artículo científico publicado en 2013

Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

artículo científico publicado en 2018

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

artículo científico publicado en 2015

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).

artículo científico publicado en 2018

Correction to Discovery of a Potent and SelectiveDDR1 Receptor Tyrosine Kinase Inhibitor.

artículo científico publicado en 2014

DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors

artículo científico publicado en 2014

Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors

artículo científico publicado en 2016

Discovery of a cooperative mode of inhibiting RIPK1 kinase

artículo científico publicado en 2021

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth

artículo científico publicado en 2017

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.

artículo científico publicado en 2014

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

artículo científico publicado en 2016

Identification of a potent and selective covalent Pin1 inhibitor

artículo científico publicado en 2020

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

scientific article published on 11 April 2019

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

artículo científico publicado en 2014

Modulating TRADD to restore cellular homeostasis and inhibit apoptosis

artículo científico publicado en 2020

Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma

artículo científico publicado en 2019

Structure-guided development of covalent TAK1 inhibitors

artículo científico publicado en 2016

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors

artículo científico publicado en 2016

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.

artículo científico publicado en 2017

Lista de obras de

4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss

Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).

Correction to Discovery of a Potent and SelectiveDDR1 Receptor Tyrosine Kinase Inhibitor.

DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors

Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors

Discovery of a cooperative mode of inhibiting RIPK1 kinase

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

Identification of a potent and selective covalent Pin1 inhibitor

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

Modulating TRADD to restore cellular homeostasis and inhibit apoptosis

Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma

Structure-guided development of covalent TAK1 inhibitors

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.